Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 5:20 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 959 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Arm 1- Dose Escalation Clear all

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, AML, MDS, CMML
Interventions: CFI-400945, Azacitidine; Drug
Lead sponsor: Treadwell Therapeutics, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 6
States / cities: Duarte, California • Sacramento, California • Louisville, Kentucky + 3 more

Conditions: Prostate Cancer, Localized Prostate Carcinoma
Interventions: Microboost SBRT, Whole gland de-escalation 30 Gy, Whole gland de-escalation 35 Gy; Radiation
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2035
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Advanced Solid Tumors Cancer
Interventions: Osimertinib, Nivolumab, Telisotuzumab vedotin, Erlotinib; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 237 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2026
U.S. locations: 21
States / cities: Scottsdale, Arizona • Duarte, California • Los Angeles, California + 17 more

Conditions: Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Neuroblastoma, Solid Tumors
Interventions: Idasanutlin, Venetoclax, Cyclophosphamide, Topotecan, Fludarabine, Cytarabine, Intrathecal Chemotherapy; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 0 Years to 30 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 5
States / cities: Little Rock, Arkansas • Palo Alto, California • Orlando, Florida + 2 more

Conditions: Multiple Myeloma
Interventions: Cevostamab, Tocilizumab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 355 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 10
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Duarte, California + 6 more

Conditions: Breast Cancer, Breast Adenocarcinoma, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Recurrent Breast Carcinoma, Stage IV Breast Cancer
Interventions: Rebastinib, Paclitaxel, Eribulin Mesylate; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Pompe Disease
Interventions: VAL-1221, RhGAA; Drug
Lead sponsor: Valerion Therapeutics, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 2
States / cities: Orange, California • Durham, North Carolina

Conditions: Lymphoma, Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Burkitt Lymphoma
Interventions: Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, Revlimid (lenalidomide); Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2029
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: AL Amyloidosis
Interventions: Bendamustine, Dexamethasone; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 6
States / cities: Boston, Massachusetts • Detroit, Michigan • New York, New York

Conditions: Metastatic Breast Cancer
Interventions: BMK120, Capecitabine, BYL719, Trastuzumab, Lapatinib; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Durham, North Carolina

Conditions: Diabetes Mellitus, Type 1
Interventions: GSK189075, placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: San Diego, California

Conditions: Acute Myeloid Leukemia, Chronic Myeloid Leukemia
Interventions: PRI-724; Drug
Lead sponsor: Prism Pharma Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 6
States / cities: Atlanta, Georgia • Worcester, Massachusetts • Albuquerque, New Mexico + 3 more

Conditions: AML/MDS, Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interventions: Danvatirsen, Danvatirsen + Venetoclax; Drug · Combination Product
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2030
U.S. locations: 2
States / cities: The Bronx, New York • Houston, Texas

Conditions: Glioblastoma Multiforme
Interventions: CAR.B7-H3T cells infusion; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Follicular Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Waldenstrom Macroglobulinemia, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Indolent Lymphoma, Refractory B-Cell Lymphoma, MALT Lymphoma
Interventions: PSB202; Drug
Lead sponsor: Qilu Puget Sound Biotherapeutics (dba Sound Biologics); Industry
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 2
States / cities: Louisville, Kentucky • New York, New York

Conditions: Breast Cancer
Interventions: [68Ga]Ga-NeoB, [177Lu]Lu-NeoB, Ribociclib, Fulvestrant, Goserelin; Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 2
States / cities: Los Angeles, California • Houston, Texas

Conditions: Retinal Dystrophy, PRPF31 Mutationassociated Retinal Dystrophy, RP11
Interventions: VP-001; Drug
Lead sponsor: PYC Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 6
States / cities: Jacksonville, Florida • Miami, Florida • Ann Arbor, Michigan + 3 more

Conditions: Metastatic Bone Lesion
Interventions: Stereotactic Body Radiation Therapy; Radiation
Lead sponsor: Paul W. Read, MD; Other
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Healthy
Interventions: PF-06649751; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Tumor
Interventions: belinostat, 5-Fluorouracil (5-FU); Drug
Lead sponsor: Valerio Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 3
States / cities: Scottsdale, Arizona • Omaha, Nebraska • Portsmouth, New Hampshire

Conditions: Solid Tumors, GI Cancer
Interventions: CGX1321, Pembrolizumab, encorafenib, cetuximab; Drug
Lead sponsor: Curegenix Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 25
States / cities: Long Beach, California • Santa Rosa, California • Denver, Colorado + 21 more

Conditions: Leukemia
Interventions: clofarabine, gemtuzumab ozogamicin; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years to 60 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2015
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Refractory Ovarian Cancer With Recurrent Symptomatic Malignant Ascites
Interventions: BAX69 Single-Route Arm, BAX69 Double-Route Arm; Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 6
States / cities: Miami, Florida • Augusta, Georgia • Silver Spring, Maryland + 3 more

Conditions: Metastatic Hepatocellular Carcinoma, Local Advanced Hepatocellular Carcinoma, Alpha-fetoprotein (AFP)-Producing Gastric Cancer, Extragonadal Yolk Sac Tumors, Glypican-3 (GPC3)-Positive Squamous Non-small Cell Lung Cancer
Interventions: BGB-B2033, Tislelizumab, Bevacizumab; Drug
Lead sponsor: BeOne Medicines; Industry
Eligibility: 18 Years and older
Enrollment: 630 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 8
States / cities: Birmingham, Alabama • Goodyear, Arizona • Duarte, California + 5 more

Search by objective public record fields.

A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML

MRI-based Focal Intraprostatic Simultaneous Integrated Boost (SIB) Intensification With De-escalated Adaptive-risk SBRT for Patients With Low to Intermediate Risk Prostate Cancer

A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors

A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors

Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)

Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer

VAL-1221 Delivered Intravenously in Ambulatory and Ventilator-free Participants With Late-Onset Pompe Disease

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma

Bendamustine and Dexamethasone in Patients With Relapsed AL Amyloidosis

Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast Cancer

A Study to Assess the Safety of Single Doses of GSK189075 in Subjects With Type 1 Diabetes Mellitus

Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid Malignancies

Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML

Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc

PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies

[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer

SAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects

Phase 1/2 Study to Determine Optimal Dose for Treating Bone Metastases Using Novel STAT-RT Workflow

A Phase I Trial to Investigate the Safety and Tolerability of PF-06649751

Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors

CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)

Clofarabine and Gemtuzumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Phase 1/2a Two-Arm Dose-Escalation Study of BAX69 in Subjects With Malignant Ascites of Ovarian Cancer

A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors